Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Special Relationship with NEJM

This article was originally published in RPM Report

Executive Summary

Under Commissioner Hamburg, the New England Journal of Medicine has been a common vehicle for the agency’s public health messages. Here is the back story.

You may also be interested in...

“Grades” for FDA Approvals: When Academics Weigh in on Regulation

Physicians and patients need a better understanding of the quality of clinical trial design and data used to approve drugs, say researchers in a study published in JAMA. That led them to suggest a grading system to add another layer of information to FDA approvals, adding another academic suggestion for elaborating, explaining and embellishing FDA action.

A Tale of Two Drugs: Meridia and Avandia, and the Issues that Separated Them

Avandia and Meridia are different drugs with parallel regulatory histories: both are long-marketed treatments for metabolic disease. Both have an increased risk of cardiovascular events. And both were considered for withdrawal at roughly the same time by the same FDA division. But while there were many similarities between the two, the reviews were markedly different with markedly different outcomes.

How FDA Withdraws A Drug

FDA is weighing whether to pull GlaxoSmithKline's Avandia and Abbott Laboratories' Meridia off the market. Past examples demonstrate the final decision on whether to remove a drug or keep it on the market is a messy process made by a select number of government officials.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts